Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.93), $0.11 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $18.8 million versus the consensus estimate of $15.39 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.